Apis Capital Advisors LLC Invests $1.62 Million in Delcath Systems, Inc. (NASDAQ:DCTH)

Apis Capital Advisors LLC purchased a new stake in Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 134,400 shares of the company's stock, valued at approximately $1,618,000. Delcath Systems makes up 1.1% of Apis Capital Advisors LLC's investment portfolio, making the stock its 22nd largest holding. Apis Capital Advisors LLC owned about 0.42% of Delcath Systems as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the business. Quarry LP purchased a new stake in shares of Delcath Systems in the fourth quarter valued at approximately $34,000. Quantbot Technologies LP purchased a new stake in Delcath Systems in the 4th quarter worth $66,000. Barclays PLC acquired a new position in Delcath Systems during the third quarter worth $104,000. Jane Street Group LLC purchased a new position in Delcath Systems during the third quarter valued at $110,000. Finally, Private Advisor Group LLC acquired a new stake in shares of Delcath Systems in the fourth quarter valued at about $153,000. Institutional investors and hedge funds own 61.12% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on DCTH shares. HC Wainwright upped their price target on shares of Delcath Systems from $22.00 to $24.00 and gave the stock a "buy" rating in a research report on Friday, March 7th. Craig Hallum raised their target price on Delcath Systems from $18.00 to $21.00 and gave the company a "buy" rating in a research report on Friday, January 17th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $22.75.

Delcath Systems Trading Up 2.6 %

DCTH opened at $12.40 on Friday. The firm has a market capitalization of $414.57 million, a PE ratio of -9.19 and a beta of 0.85. Delcath Systems, Inc. has a twelve month low of $5.30 and a twelve month high of $16.97. The firm's 50-day moving average price is $12.42 and its 200 day moving average price is $12.49.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last issued its earnings results on Thursday, March 6th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01). Delcath Systems had a negative return on equity of 338.16% and a negative net margin of 150.70%. The company had revenue of $15.10 million for the quarter, compared to analyst estimates of $14.96 million. During the same quarter in the prior year, the firm earned ($0.48) earnings per share. As a group, analysts predict that Delcath Systems, Inc. will post -0.79 earnings per share for the current fiscal year.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Want to see what other hedge funds are holding DCTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Delcath Systems, Inc. (NASDAQ:DCTH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.